The latest tempest over a dramatic drug price hike riles two powerful senators — who can’t actually do anything about it

The latest tempest over a dramatic drug price hike riles two powerful senators — who can’t actually do anything about it

Source: 
Endpoints
snippet: 

First Nostrum CEO Nirmal Mulye caught the attention of FDA commissioner Scott Gottlieb when he jacked up the price of an old antibiotic from $474.75 to $2,392 last month. Now he has a pair of angry US senators on the warpath over his controversial, Martin Shkreli-like comments about the “moral requirement” of earning money for his investors and comparing the move to pricing art.